SciClone Reveals Second Subpoena For China Bribery Allegations
This article was originally published in PharmAsia News
Executive Summary
U.S. anti-corruption authorities have issued another subpoena to SciClone Pharmaceuticals related to allegations it violated the Foreign Corrupt Practices Act by making bribes in China.